Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BRCA2
REST API REST API
Homo sapiens
BRCA2 is differentially expressed in 259 experiments: 94 organism parts: bone marrow, skin, ... (92 more);, 154 disease states: normal, acute lymphoblastic leukemia, ... (152 more);, 74 cell types 313 cell lines 35 compound treatments and 79 other conditions.
Synonyms FANCD1, BRCC2, FAD1, FACD, FANCD, FAD
Orthologs Brca2 (Mus musculus)   BRCA2 (Bos taurus)   brca2 (Danio rerio)   BRCA2 (Gallus gallus)   Brca2 (Rattus norvegicus)   brca2 (Xenopus laevis)   NP_001006654.2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term male meiosis I, double-strand break repair via homologous recombination, protein binding, DNA repair, cytoplasm, cell proliferation, DNA damage response, signal transduction resulting in induction of apoptosis, spermatogenesis, female gonad development, single-stranded DNA binding, double-strand break repair, replication fork protection, multicellular organism growth, response to nutrient, hemopoiesis, positive regulation of mitotic cell cycle, DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis, nucleus, DNA recombination, oocyte maturation, response to DNA damage stimulus, response to gamma radiation, response to X-ray, brain development, chromosome organization, inner cell mass cell proliferation, cell aging, DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator, mammary gland development, response to UV-C, chordate embryonic development, regulation of cytokinesis, regulation of S phase of mitotic cell cycle, response to estradiol stimulus, homologous chromosome orientation involved in meiotic metaphase I plate congression
InterPro Term BRCA2_repeat, DNA_recomb/repair_BRCA2_hlx, DNA_recomb/repair_BRCA2, Tower, BRCA2_OB_1, BRCA2_OB_3
UniProt Accession Q9H4L3, B2ZAH0, Q8IU82, Q8IU77, Q8IU64, P51587, E9PIQ1
Gene-Disease Assocation PANCREATIC CANCER, PROSTATE CANCER, BREAST CANCER, PANCREATIC CANCER, SUSCEPTIBILITY TO, 2, WILMS TUMOR 1; WT1, GLIOMA SUSCEPTIBILITY 1; GLM1, FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1, GLIOMA SUSCEPTIBILITY 3; GLM3, BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2, MEDULLOBLASTOMA; MDB, FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA
Search EB-eye ENSG00000139618
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MEXP-433, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
Daudi
2
E-MTAB-37, E-GEOD-96
Jurkat
2
E-GEOD-1880, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MTAB-37, E-MEXP-1014
307 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-993, E-MEXP-66, E-GEOD-4219, E-GEOD-20677, ... (38 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-MTAB-25, E-GEOD-6740
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD133+ prostate epithelial cell
1
1
E-MEXP-993
erythropoietic
1
E-GEOD-9894
CD14+ monocyte
3
1
E-AFMX-5
68 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-MEXP-25, E-GEOD-15960, E-GEOD-5563, ... (48 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-37
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
neuroblastoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
melanoma
2
E-MTAB-62, E-MTAB-37
acute lymphoblastic leukemia
1
2
E-MTAB-37, E-MTAB-62, E-GEOD-96
148 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
estradiol
1
E-GEOD-20081
U0126
1
E-GEOD-697
MIG control
1
E-GEOD-15811
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
CNOT7+CNOT8
1
1
E-MEXP-2218
no estradiol
1
E-GEOD-20081
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-4619, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1923, E-GEOD-3494, E-GEOD-18736, E-TABM-868, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-12773, E-GEOD-20504, E-MEXP-1446, E-GEOD-19018, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-TABM-15, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-6802

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-4600 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.507 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM